Suzanne Chaves, MD
Endocrinology, Diabetes & Metabolism · Rancho Mirage, CANPI 1851390058
Payments from drug & device makers
What this record shows
This record is dominated by travel and lodging: $352 of the $522 with a category attached, or 67.4%. Astrazeneca UK Limited accounts for 92.4% of it on its own, with 2 other manufacturers making up the rest. 2022 is the largest year on record at $482, more than ten times the $19 reported in 2019. That places this record below the midpoint for endocrinology, diabetes & metabolism clinicians in CA, where the typical reported total is $1,096.
Across 5 payments — averaging $104.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Astrazeneca UK Limited$482
- AstraZeneca$21
- Sanofi-aventis U.S. LLC$19
Across 12 payments — averaging $48,427 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Dexcom, Inc.$484K
- Eli Lilly$61K
- Astrazeneca UK Limited$37K
What the payments were for
- Travel & lodging$35267%
- Food & beverage$17033%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Astrazeneca UK Limited | 3 | $482 |
| AstraZeneca | 1 | $21 |
| Sanofi-aventis U.S. LLC | 1 | $19 |
How this compares
$522 in reported general payments places this provider in the 35th percentile of 952 endocrinology, diabetes & metabolism providers in California.
See all endocrinology, diabetes & metabolism providers in California →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 83 | $149,930 |
| TrulicityDulaglutide | 45 | $99,536 |
| TymlosAbaloparatide | 14 | $78,825 |
| JardianceEmpagliflozin | 51 | $71,980 |
| MounjaroTirzepatide | 47 | $54,483 |
| FarxigaDapagliflozin Propanediol | 15 | $22,560 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 11 | $19,289 |
| Xigduo XrDapaglifloz Propaned/Metformin | 14 | $17,535 |
| Tresiba Flextouch U-200Insulin Degludec | 16 | $12,237 |
| Tresiba Flextouch U-100Insulin Degludec | 11 | $8,202 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 11 | $6,414 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 17 | $2,229 |
| Metformin Hcl ErMetformin Hcl | 56 | $1,926 |
| Nano 2nd Gen Pen NeedlePen Needle, Diabetic | 20 | $1,518 |
| Risedronate Sodium | 18 | $1,307 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga | $21 | $22,56015 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 952 endocrinology, diabetes & metabolism providers in California.
Other endocrinology, diabetes & metabolism in Rancho Mirage
- Helen BaronRancho Mirage$958K
- Juan FriasSan Diego$1.4M
- Joselito CabaccanSan Jose$1.4M
- Daniel NadeauNewport Beach$1.2M
- Yehuda HandelsmanTarzana$1M
- Ken FujiokaSan Diego$747K
- Minou TranPico Rivera$663K
- James ChuMonterey$639K
- Anthony HeaneyLos Angeles$588K
- Daniel Einhornla Jolla$578K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.